Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BFLYNASDAQ:DCGONASDAQ:FMTXNASDAQ:REPL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFLYButterfly Network$2.52-3.6%$2.34$0.82▼$4.98$621.93M2.543.05 million shs3.61 million shsDCGODocGo$1.53$1.89$1.23▼$5.68$156.03M0.94787,559 shs691,583 shsFMTXForma Therapeutics$20.01$20.00$4.95▼$20.68$957.54M-0.94847,595 shs1 shsREPLReplimune Group$9.78-3.5%$8.50$6.44▼$17.00$753.91M0.63909,889 shs1.20 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFLYButterfly Network-3.82%+5.67%+7.25%-1.57%+169.59%DCGODocGo0.00%+6.25%+5.88%-46.69%-52.63%FMTXForma Therapeutics0.00%0.00%0.00%0.00%0.00%REPLReplimune Group-3.46%+0.93%+24.43%-17.54%+8.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBFLYButterfly Network2.1014 of 5 stars3.51.00.00.01.82.50.6DCGODocGo3.473 of 5 stars3.33.00.00.03.02.51.9FMTXForma TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AREPLReplimune Group4.1442 of 5 stars3.61.00.04.52.82.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFLYButterfly Network 3.00Buy$4.0059.05% UpsideDCGODocGo 2.50Moderate Buy$3.56132.68% UpsideFMTXForma Therapeutics 0.00N/AN/AN/AREPLReplimune Group 3.14Buy$20.83113.02% UpsideCurrent Analyst Ratings BreakdownLatest BFLY, FMTX, DCGO, and REPL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025REPLReplimune GroupPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$14.00 ➝ $22.005/12/2025DCGODocGoCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$5.00 ➝ $1.455/9/2025DCGODocGoNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$4.00 ➝ $3.005/9/2025DCGODocGoBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/5/2025BFLYButterfly NetworkLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $4.004/8/2025DCGODocGoNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/17/2025BFLYButterfly NetworkWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFLYButterfly Network$85.63M7.26N/AN/A$1.06 per share2.37DCGODocGo$520.50M0.30$0.06 per share23.62$2.93 per share0.52FMTXForma Therapeutics$100.56M9.52N/AN/A$10.51 per share1.90REPLReplimune GroupN/AN/AN/AN/A$6.26 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFLYButterfly Network-$133.70M-$0.29N/AN/AN/A-129.25%-42.68%-30.31%8/7/2025 (Estimated)DCGODocGo$6.86M-$0.025.4619.1314.164.35%8.90%5.72%8/6/2025 (Estimated)FMTXForma Therapeutics-$172.96M-$4.00N/AN/AN/AN/A-39.68%-35.33%N/AREPLReplimune Group-$215.79M-$3.07N/AN/AN/AN/A-54.84%-42.97%8/6/2025 (Estimated)Latest BFLY, FMTX, DCGO, and REPL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2025Q4 2025REPLReplimune Group-$0.75-$0.82-$0.07-$0.82N/AN/A5/8/2025Q1 2025DCGODocGo-$0.01-$0.09-$0.08-$0.09$104.25 million$96.03 million5/2/2025Q1 2025BFLYButterfly Network-$0.09-$0.06+$0.03-$0.06$21.16 million$21.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBFLYButterfly NetworkN/AN/AN/AN/AN/ADCGODocGoN/AN/AN/AN/AN/AFMTXForma TherapeuticsN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFLYButterfly NetworkN/A4.662.95DCGODocGoN/A2.192.19FMTXForma TherapeuticsN/A12.7412.74REPLReplimune Group0.1411.4311.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFLYButterfly Network37.85%DCGODocGo56.44%FMTXForma Therapeutics87.39%REPLReplimune Group92.53%Insider OwnershipCompanyInsider OwnershipBFLYButterfly Network25.18%DCGODocGo2.70%FMTXForma Therapeutics5.79%REPLReplimune Group8.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBFLYButterfly Network460247.29 million154.94 millionOptionableDCGODocGo2,920101.98 million99.30 millionOptionableFMTXForma Therapeutics16647.85 million45.08 millionNot OptionableREPLReplimune Group21077.09 million70.24 millionOptionableBFLY, FMTX, DCGO, and REPL HeadlinesRecent News About These CompaniesReplimune Group, Inc. Grants Inducement Equity Awards to New Employees Under 2025 PlanJune 6, 2025 | quiverquant.comReplimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 6, 2025 | globenewswire.comReplimune Group (NASDAQ:REPL) Shares Gap Up - Time to Buy?June 4, 2025 | marketbeat.comPiper Sandler Increases Replimune Group (NASDAQ:REPL) Price Target to $22.00June 4, 2025 | americanbankingnews.comWellington Management Group LLP Grows Position in Replimune Group, Inc. (NASDAQ:REPL)June 3, 2025 | marketbeat.comContrasting Ablynx (OTCMKTS:ABLYF) & Replimune Group (NASDAQ:REPL)June 3, 2025 | americanbankingnews.comPiper Sandler Issues Positive Forecast for Replimune Group (NASDAQ:REPL) Stock PriceJune 2, 2025 | marketbeat.comReplimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingJune 1, 2025 | globenewswire.comTwo Sigma Investments LP Buys 33,346 Shares of Replimune Group, Inc. (NASDAQ:REPL)June 1, 2025 | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of "Buy" from AnalystsJune 1, 2025 | marketbeat.comReplimune Group (NASDAQ:REPL) Stock Price Down 5.9% - Time to Sell?May 31, 2025 | marketbeat.comReplimune Group (NASDAQ:REPL) Stock Price Up 5.4% - Here's WhyMay 30, 2025 | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Nuveen Asset Management LLCMay 30, 2025 | marketbeat.comReplimune to Present at the 2025 Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comHC Wainwright Estimates Replimune Group Q3 EarningsMay 27, 2025 | marketbeat.comLeerink Partnrs Estimates Replimune Group Q1 EarningsMay 27, 2025 | marketbeat.comReplimune’s SWOT analysis: biotech firm’s stock poised for growth amid FDA reviewMay 26, 2025 | investing.comReplimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Woodline Partners LPMay 25, 2025 | marketbeat.comMillennium Management LLC Acquires 34,841 Shares of Replimune Group, Inc. (NASDAQ:REPL)May 25, 2025 | marketbeat.comReplimune Group (NASDAQ:REPL) Shares Gap Up - Here's WhyMay 24, 2025 | marketbeat.comTraders Buy High Volume of Replimune Group Call Options (NASDAQ:REPL)May 24, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBFLY, FMTX, DCGO, and REPL Company DescriptionsButterfly Network NYSE:BFLY$2.52 -0.10 (-3.64%) Closing price 06/11/2025 03:59 PM EasternExtended Trading$2.53 +0.01 (+0.44%) As of 06/11/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. It offers Butterfly iQ, a handheld and single-probe whole body ultrasound system; Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging in a single handheld probe integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and almost any hospital computer system; and Butterfly iQ+ Vet, a handheld ultrasound system designed for veterinarians. The company also provides Butterfly system, which includes probes, and related accessories and software subscriptions to healthcare systems, physicians, and healthcare providers through a direct sales force, distributors, and eCommerce channel. In addition, it offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials, and formal education programs through its Butterfly Academy software, as well as professional services for large scale deployments; and ScanLab, an education-only app provides written walkthroughs and reference imagery to guide real-time educational scanning, enhancing the learning process. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.DocGo NASDAQ:DCGO$1.53 0.00 (0.00%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$1.58 +0.05 (+3.27%) As of 06/11/2025 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home, offices, and other locations; event services, which include on-site healthcare support at sporting events and concerts; and total care management solutions comprising healthcare services and ancillary services, such as shelter. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.Forma Therapeutics NASDAQ:FMTXForma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.Replimune Group NASDAQ:REPL$9.78 -0.35 (-3.46%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$9.96 +0.18 (+1.84%) As of 06/11/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why a Trump-Musk Feud Could Mean Big Wins for AST SpaceMobile Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAY GitLab: Buy It Low While You Still Can—Higher Prices Are Coming RKLB Breakout Fails Near Highs: Should Investors Be Concerned? Amazon Is on Track to Hit a Critical Level: Watch Out Tesla Stock: Why These 2 Downgrades Are Actually a Buy Signal Nintendo Stock Near Highs—Will the Switch 2 Keep the Rally Alive? Will Warner Bros. Discovery’s Split Produce Double the Upside? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
